Alzamend Neuro, Inc. (ALZN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Alzamend Neuro, Inc., an emerging growth company incorporated in Delaware, on October 9, 2025. The report covers events occurring between October 1, 2025, and October 8, 2025.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a specific equity transaction.
Material Changes
- Unregistered Sales of Equity Securities: Between October 1 and October 8, 2025, the Company issued 361,743 shares of Common Stock.
- Conversion Details: These shares were issued upon the conversion of approximately 839.2 shares of Series B Convertible Preferred Stock.
- Regulatory Basis: The issuance relied on the exemption from registration requirements under Section 4(a)(2) of the Securities Act.
- Capital Structure Update: As of October 8, 2025, the total number of Common Stock shares outstanding was 3,801,604.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a procedural disclosure of a stock conversion event.
Investor Verification Checklist
- Verify the total outstanding share count of 3,801,604 as of October 8, 2025.
- Confirm the conversion ratio and terms of the Series B Convertible Preferred Stock.
- Review the Company's cash position to assess the impact of the increased share count on dilution.
- Check for any subsequent filings regarding the Series B Preferred Stock balance.